nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis
|
Zhou, Susu |
|
|
19 |
4 |
p. 547-564 |
artikel |
2 |
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab
|
Persano, Mara |
|
|
19 |
4 |
p. 645-659 |
artikel |
3 |
Anti-Angiogenic Tyrosine Kinase Inhibitor-Related Toxicities Among Cancer Patients: A Systematic Review and Meta-Analysis
|
Van Nguyen, Tai |
|
|
19 |
4 |
p. 533-545 |
artikel |
4 |
A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma
|
Gupta, Shilpa |
|
|
19 |
4 |
p. 483-494 |
artikel |
5 |
Comment on: “Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer”
|
Han, Wei |
|
|
19 |
4 |
p. 661-662 |
artikel |
6 |
Correction to: Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer
|
Li, Yuan |
|
|
19 |
4 |
p. 663 |
artikel |
7 |
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma
|
Uchimoto, Taizo |
|
|
19 |
4 |
p. 635-644 |
artikel |
8 |
Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer
|
Li, Yuan |
|
|
19 |
4 |
p. 601-610 |
artikel |
9 |
Impact of PD-L1 Expression on the Overall Survival of Caucasian Patients with Advanced EGFR-Mutant NSCLC Treated with Frontline Osimertinib
|
Papazyan, Thomas |
|
|
19 |
4 |
p. 611-621 |
artikel |
10 |
Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review
|
Fowler, Nathan Hale |
|
|
19 |
4 |
p. 495-510 |
artikel |
11 |
Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study
|
Kagawa, Yoshinori |
|
|
19 |
4 |
p. 575-585 |
artikel |
12 |
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)
|
Fiala, Ondřej |
|
|
19 |
4 |
p. 587-599 |
artikel |
13 |
Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group
|
Salgado Fernández, Mercedes |
|
|
19 |
4 |
p. 565-573 |
artikel |
14 |
Survival Impact of Glucocorticoid Administration for Adverse Events During Immune Checkpoint Inhibitor Combination Therapy in Patients with Previously Untreated Advanced Renal Cell Carcinoma
|
Yoshino, Maki |
|
|
19 |
4 |
p. 623-633 |
artikel |
15 |
Targeted Alpha Therapy for Glioblastoma: Review on In Vitro, In Vivo and Clinical Trials
|
Sabri, Maram El |
|
|
19 |
4 |
p. 511-531 |
artikel |